AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04223661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
Study NCT04223661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
Study NCT05348642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pasteurized A. muciniphila
Description: pasteurized A. muciniphila - oral daily dose
Study NCT05348642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo = identical to verum regarding the form, size, taste, color and intake
Study NCT04825509 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line.
Study NCT06043999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical total mesorectal excision
Description: Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
Study NCT06043999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salavge Adjuvant Chemoradiotherapy
Description: Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
Study NCT06526767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules twice a week
Description: Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
Study NCT06526767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules three times a week
Description: Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
Study NCT06526767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules five times a week
Description: Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
Study NCT06526767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsules loading dose
Description: Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
Study NCT06529523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
Study NCT05483439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Study NCT05772793 — intervention group
Intervention type: DEVICE
Intervention: Telerehabilitation
Description: The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
Study NCT06467045 — intervention group
Intervention type: OTHER
Intervention: Pediatric patients who received sedation for magnetic resonance imaging
Description: Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
Study NCT06388876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
Study NCT05123365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Given PO
Study NCT05483439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Study NCT05000164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch + Lomb Ultra® Multifocal for Astigmatism
Description: Study Lens
Study NCT04118387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide + supplemental oxygen + PAP therapy
Description: Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
Study NCT04118387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem + PAP therapy
Description: The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
Study NCT04118387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone + PAP therapy
Description: The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
Study NCT06388876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle advice
Description: At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
Study NCT05827809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression
Description: A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
Study NCT06388577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
Study NCT04652115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Deibrotide via IV
Study NCT05483439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Study NCT05483439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Study NCT05483439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional herbal medicine
Description: traditional herbal medicine
Study NCT04976049 — intervention group
Intervention type: PROCEDURE
Intervention: Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery
Description: Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
Study NCT06259929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG + Giredestrant 30 MG
Description: Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
Study NCT05824156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 mg/kg CM-101
Description: CM-101, Monoclonal Ab blocking CCL24
Study NCT05824156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06044259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMDS; Artivion, Atlanta, Georgia, US
Description: Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
Study NCT06044259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemiarch replacement
Description: Coventional open hemiarch replacement
Study NCT05741268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
Study NCT05741268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavior therapy
Description: 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
Study NCT06392022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching cartoons with music
Description: The purpose of this study was to evaluate the effect of watching musical cartoons on anxiety and vital signs in children undergoing rectal irrigation.
Study NCT06209190 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow and total lymphoid irradiation
Description: doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
Study NCT04593888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten reduced diet
Description: Dietary advice focusing on reducing gluten intake in children
Study NCT06092996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of Sling Use
Description: Standard sling worn for only three days post operatively
Study NCT05147818 — intervention group
Intervention type: OTHER
Intervention: CBC ,renal function tests , fundus Examination
Description: Laboratory investigations
Study NCT05266911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity functional strength training
Description: HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
Study NCT05266911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower extremity stretching
Description: Lower extremity stretching program to be completed by participants at home 3 days per week.
Study NCT05550558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Camrelizumab
Description: Anlotinib PO plus Camrelizumab IV
Study NCT04820673 — intervention group
Intervention type: DRUG
Intervention: Sarecycline
Description: Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
Study NCT04901611 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parental touch
Description: Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
Study NCT04901611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental touch
Description: Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
Study NCT05948150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using a breastfeeding pillow
Description: To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
Study NCT04564833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose RBT-1
Description: intravenous administration
Study NCT04564833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose RBT-1
Description: intravenous administration
Study NCT04564833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous administration
Study NCT04897295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
Study NCT06263465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus cispatus
Description: 10\^9 cfu,5 days
Study NCT04897295 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
Study NCT06263465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0 cfu,5 days
Study NCT05934045 — intervention group
Intervention type: BIOLOGICAL
Intervention: RNAseq
Description: there is no intervention done.
Study NCT05948150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: not using a breastfeeding pillow
Description: The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
Study NCT05159531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
Study NCT04812704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Patient receive protein supplement in liquid form after each exercice session
Study NCT06530082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CircFam53B-219aa DC vaccine
Description: Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.
Study NCT06530082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
Study NCT05159531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP
Description: Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
Study NCT05159531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Model of Care
Description: Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.
Study NCT05159531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Delivery of PrEP care through the local standard of care
Study NCT05685147 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Non-invasive Preimplantation genetic testing for aneuploidy status
Description: In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
Study NCT05105477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcumenTM HPI Software Feature
Description: The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
Study NCT05986604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support Intervention
Description: The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Study NCT05986604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
Study NCT05105477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-protocolized Standard of Care
Description: Non-protocolized standard of care to treat subjects
Study NCT05986604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.